Minji Choi1, Yoo Hong Min1, Jaehyuk Pyo1, Chang-Woo Lee2, Chang-Young Jang3, Ja-Eun Kim1,4,5. 1. Department of Biomedical Science, Graduate School, Kyung Hee University, Seoul, Republic of Korea. 2. Department of Molecular Cell Biology, School of Medicine, Sungkyunkwan University, Suwon, Republic of Korea. 3. College of Pharmacy, Sookmyung Women's University, Seoul, Republic of Korea. 4. East-West Medical Research Institute, Kyung Hee University, Seoul, Republic of Korea. 5. Department of Pharmacology, School of Medicine, Kyung Hee University, Seoul, Republic of Korea.
Abstract
BACKGROUND AND PURPOSE: Chromosomal instability is not only a hallmark of cancer but also an attractive therapeutic target. A diverse set of mitotic kinases maintains chromosomal stability. One of these is monopolar spindle 1 (Mps1, also known as TTK), which is essential for chromosome alignment and for the spindle assembly checkpoint (SAC). Pharmacological inhibition of Mps1 has been suggested as a cancer therapeutic; however, despite the existence of a novel Mps1 inhibitor, TC Mps1 12, no such studies have been performed. EXPERIMENTAL APPROACH: The effects of TC Mps1 12 on cell viability, chromosome alignment, centrosome number, mitotic duration, apoptosis and SAC were determined in hepatocellular carcinoma (HCC) cells. In addition, the association of Mps1 expression with the overall survival of HCC patients was analysed. KEY RESULTS: Treatment of human HCC cells with TC Mps1 12 led to chromosome misalignment and missegregation, and disorganization of centrosomes. Even in the presence of these errors, TC Mps1 12-treated cells overrode the SAC, resulting in a shortened mitotic duration and mitotic slippage. This mitotic catastrophe triggered apoptosis and, finally, inhibited the growth of HCC cells. In addition, the expression of the Mps1-encoding TTK gene was associated with poor overall survival of HCC patients. CONCLUSION AND IMPLICATIONS: TC Mps1 12 results in the accumulation of chromosomal instabilities and mitotic catastrophe in HCC cells. Overall, these data demonstrate that the inhibition of Mps1 kinase using TC Mps1 12 is a promising therapeutic approach for liver cancer.
BACKGROUND AND PURPOSE: Chromosomal instability is not only a hallmark of cancer but also an attractive therapeutic target. A diverse set of mitotic kinases maintains chromosomal stability. One of these is monopolar spindle 1 (Mps1, also known as TTK), which is essential for chromosome alignment and for the spindle assembly checkpoint (SAC). Pharmacological inhibition of Mps1 has been suggested as a cancer therapeutic; however, despite the existence of a novel Mps1 inhibitor, TC Mps1 12, no such studies have been performed. EXPERIMENTAL APPROACH: The effects of TC Mps1 12 on cell viability, chromosome alignment, centrosome number, mitotic duration, apoptosis and SAC were determined in hepatocellular carcinoma (HCC) cells. In addition, the association of Mps1 expression with the overall survival of HCC patients was analysed. KEY RESULTS: Treatment of human HCC cells with TC Mps1 12 led to chromosome misalignment and missegregation, and disorganization of centrosomes. Even in the presence of these errors, TC Mps1 12-treated cells overrode the SAC, resulting in a shortened mitotic duration and mitotic slippage. This mitotic catastrophe triggered apoptosis and, finally, inhibited the growth of HCC cells. In addition, the expression of the Mps1-encoding TTK gene was associated with poor overall survival of HCC patients. CONCLUSION AND IMPLICATIONS: TC Mps1 12 results in the accumulation of chromosomal instabilities and mitotic catastrophe in HCC cells. Overall, these data demonstrate that the inhibition of Mps1 kinase using TC Mps1 12 is a promising therapeutic approach for liver cancer.
Authors: Stefan Kemmler; Manuel Stach; Maria Knapp; Jennifer Ortiz; Jens Pfannstiel; Thomas Ruppert; Johannes Lechner Journal: EMBO J Date: 2009-03-19 Impact factor: 11.598
Authors: Iina Niittymäki; Alexandra Gylfe; Leena Laine; Marko Laakso; Heli J Lehtonen; Johanna Kondelin; Jaana Tolvanen; Kari Nousiainen; Jeroen Pouwels; Heikki Järvinen; Kyösti Nuorva; Jukka-Pekka Mecklin; Markus Mäkinen; Ari Ristimäki; Torben F Ørntoft; Sampsa Hautaniemi; Auli Karhu; Marko J Kallio; Lauri A Aaltonen Journal: Carcinogenesis Date: 2010-12-16 Impact factor: 4.944
Authors: Laura Hewitt; Anthony Tighe; Stefano Santaguida; Anne M White; Clifford D Jones; Andrea Musacchio; Stephen Green; Stephen S Taylor Journal: J Cell Biol Date: 2010-07-12 Impact factor: 10.539
Authors: Stefano Santaguida; Anthony Tighe; Anna Morena D'Alise; Stephen S Taylor; Andrea Musacchio Journal: J Cell Biol Date: 2010-07-12 Impact factor: 10.539
Authors: Christopher Southan; Joanna L Sharman; Helen E Benson; Elena Faccenda; Adam J Pawson; Stephen P H Alexander; O Peter Buneman; Anthony P Davenport; John C McGrath; John A Peters; Michael Spedding; William A Catterall; Doriano Fabbro; Jamie A Davies Journal: Nucleic Acids Res Date: 2015-10-12 Impact factor: 16.971
Authors: Benjamin C Chandler; Leah Moubadder; Cassandra L Ritter; Meilan Liu; Meleah Cameron; Kari Wilder-Romans; Amanda Zhang; Andrea M Pesch; Anna R Michmerhuizen; Nicole Hirsh; Marlie Androsiglio; Tanner Ward; Eric Olsen; Yashar S Niknafs; Sofia Merajver; Dafydd G Thomas; Powel H Brown; Theodore S Lawrence; Shyam Nyati; Lori J Pierce; Arul Chinnaiyan; Corey Speers Journal: J Clin Invest Date: 2020-02-03 Impact factor: 14.808